AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score.
Epistemonikos ID: 3d989f648b5801d447e018fa38ae024845557e1d
First added on: May 05, 2024